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OBJECTIVE—Variation in the transcription factor 7-like 2
(TCF7L2) locus is associated with type 2 diabetes across multiple
ethnicities. The aim of this study was to elucidate which variant
in TCF7L2 confers diabetes susceptibility in African Americans.
RESEARCH DESIGN AND METHODS—Through the evalua-
tion of tagging single nucleotide polymorphisms (SNPs), type 2
diabetes susceptibility was limited to a 4.3-kb interval, which
contains the YRI (African) linkage disequilibrium (LD) block
containing rs7903146. To better deﬁne the relationship between
type 2 diabetes risk and genetic variation we resequenced this
4.3-kb region in 96 African American DNAs. Thirty-three novel
and 13 known SNPs were identiﬁed: 20 with minor allele
frequencies (MAF) .0.05 and 12 with MAF .0.10. These poly-
morphisms and the previously identiﬁed DG10S478 microsatellite
were evaluated in African American type 2 diabetic cases (n =
1,033) and controls (n = 1,106).
RESULTS—Variants identiﬁed from direct sequencing and data-
bases were genotyped or imputed. Fifteen SNPs showed asso-
ciation with type 2 diabetes (P < 0.05) with rs7903146 being the
most signiﬁcant (P = 6.32 3 10
26). Results of imputation, hap-
lotype, and conditional analysis of SNPs were consistent with
rs7903146 being the trait-deﬁning SNP. Analysis of the DG10S478
microsatellite, which is outside the 4.3-kb LD block, revealed con-
sistent association of risk allele 8 with type 2 diabetes (odds ratio
[OR] = 1.33; P = 0.022) as reported in European populations; how-
ever, allele 16 (MAF = 0.016 cases and 0.032 controls) was strongly
associated with reduced risk (OR = 0.39; P =5 . 0 23 10
25)i n
contrast with previous studies.
CONCLUSIONS—In African Americans, these observations
suggest that rs7903146 is the trait-deﬁning polymorphism associ-
ated with type 2 diabetes risk. Collectively, these results support
ethnic differences in type 2 diabetes associations. Diabetes
60:662–668, 2011
D
iabetes is estimated to affect nearly 24 million
people in the United States. This signiﬁcant
disease burden translates to a major economic
impact. Prevalence is observed disproportion-
ately across ethnicities with the some of the highest rates
observed in African Americans, i.e., 11.8% (1). Increased
risk is likely to be multifactorial, resulting from the com-
bination of shared cultural, environmental, and genetic
factors. Although recent genome-wide association studies
of type 2 diabetes in European-derived populations have
revealed novel, reproducible susceptibility loci (2–11), few
have been replicated in African Americans (12–14).
An exception to this observation is the association of the
transcription factor 7-like 2 (TCF7L2) gene with type 2
diabetes in African (15) and African-derived populations,
i.e., African Americans (12,16). TCF7L2 is a transcription
factor involved in the Wnt signaling pathway (17). Al-
though initial reports implicated TCF7L2 in the regulation
of the glucagon gene in the L cells of the gut (18), more
recent reports suggest involvement in insulin secretion
(19) potentially through epigenetic mechanisms (20). The
initial report of association between TCF7L2 and type 2
diabetes in an Icelandic cohort identiﬁed a 64-kb linkage
disequilibrium (LD) block of strong LD encompassing the
intron 3 to intron 4 region of the gene (21) in this European
population. Reﬁnement of this signal in expanded pop-
ulations revealed the strongest evidence of association
with the single nucleotide polymorphism (SNP) rs7903146
with a relative risk of 1.45–1.49 (15). Although it has been
inferred from these studies that rs7903146 is most likely the
causative variant, the large (64 kb) LD block in European-
derived populations and the large number of variants in this
region have made it challenging to deﬁnitively conclude that
variation at this SNP confers susceptibility to type 2 di-
abetes based solely upon genetic studies.
We previously reported association of TCF7L2 variants
and type 2 diabetes in a large African American case-
control cohort (16). Of the SNPs evaluated, association
was observed with rs7903146 and rs7901695 (admixture-
adjusted additive P =3 . 7 73 10
26 and 0.0030, respec-
tively) in a collection of 577 type 2 diabetic case subjects
enriched for nephropathy and 596 controls. Given the
evidence of association in our African American cohort
(12,16), we sought to reﬁne the genomic interval of TCF7L2
associated with type 2 diabetes in African Americans and,
using a comprehensive analysis of variation in TCF7L2,
to deﬁne the genetic basis for type 2 diabetes suscep-
tibility.
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ORIGINAL ARTICLERESEARCH DESIGN AND METHODS
Study subjects. This study was conducted under Institutional Review Board
approval from Wake Forest University School of Medicine. Identiﬁcation,
clinical characteristics, and recruitment of African American patients and
controls have been previously described in detail (22). Brieﬂy, 1,033 unrelated
African American patients with type 2 diabetes were recruited from dialysis
facilities. Type 2 diabetes was diagnosed in African Americans who reported
developing type 2 diabetes after the age of 25 years and who did not receive
only insulin therapy since diagnosis. In addition, cases had to have at least one
of the following three criteria for inclusion: 1) type 2 diabetes diagnosed at
least 5 years before initiating renal replacement therapy, 2) background or
greater diabetic retinopathy, and/or 3) $100 mg/dL proteinuria on urinalysis in
the absence of other causes of nephropathy. An additional 1,106 unrelated
African Americans without a current diagnosis of diabetes or renal disease
were recruited from the community and internal medicine clinics as controls.
All type 2 diabetic cases and nondiabetic controls were born in North Caro-
lina, South Carolina, Georgia, Tennessee, or Virginia. DNA extraction was
performed using the PureGene system (Gentra Systems, Minneapolis, MN).
Sequencing. The DNA screening panel was composed of 96 African American
subjects: 48 type 2 diabetic cases and 48 controls. PCR primers were designed
to independently amplify a 4.3-kb region of TCF7L2. Primer sequences are
available on request. DNA sequencing reactions were performed using BigDye
Terminator v.1.1 Cycle Sequencing Kits and analyzed on the Applied Bio-
systems 3730xl DNA Analyzer (Applied Biosystems, Foster City, CA). Se-
quencing reactions were performed on both DNA strands. Sequence alignment
and polymorphism identiﬁcation were performed using Sequencher 4.2 (Gene
Codes, Ann Arbor, MI). All polymorphisms were validated through observa-
tion on both strands. A search of the region sequenced was performed at
dbSNP (www.ncbi.nlm.nih.gov) to record all previously identiﬁed poly-
morphisms reported in the region.
Genotyping. Genotyping of DG10S478 was performed by fragment length
analysis on anABI Prism DNA Analyzer 3700 withpreviously published primers
(21) in a manner similar to that previously described (23). Fragment length
was determined using ABI Prism GeneMapper software v3.0. Fifty-six duplicate
samples were run for quality control purposes. SNP genotyping was performed
on the iPlex MassARRAY genotyping platform (Sequenom, San Diego, CA).
Blind duplicates and blanks were included for quality control and error check-
ing. For all SNPs, the genotyping success rate was greater than 95%.
Imputation. In preliminary analyses, SNPs in the TCF7L2 gene region 6 10 kb
(C10:114689999–114926060) were imputed using data from HapMap phase II
hybrid panel (1:1, YRI:CEU; 108 SNPs) and the 1000 Genomes YRI Pilot 1
dataset (497 SNPs) to circumvent limited coverage of the genetic diversity in
this speciﬁc region by the Affymetrix 6.0 array. SNPs were imputed in 965 type
2 diabetic end-stage renal disease (ESRD) cases and 1,029 controls with high-
quality score (rsq-hat $0.3) using the software MACH (www.sph.umich.edu/
csg/abecasis) (24). The imputed most likely genotypes were then used for
subsequent association tests.
Four common SNPs identiﬁed from direct sequence analysis had minor
allele frequencies (MAF) $0.05 and failed assay design on the Sequenom
platform. With the use of the resequencing genotype data obtained from the 96
African American samples as reference, these SNPs were imputed in the
remaining 2,043 samples with high-quality score (rsq-hat $0.5) using the
software MACH (www.sph.umich.edu/csg/abecasis) (24). The imputed most
likely genotypes were then used for subsequent association tests.
Analysis. SNPs were tested for departure from Hardy-Weinberg equilibrium
(HWE) using anexact test of HWE proportionsfor the combined group of cases
and controls and then for cases only and controls only (25). Those SNPs out of
HWE were noted but still included for the genotypic analysis. Haplotype block
structure was established using Haploview 4.1 (26), deﬁning blocks using the
method from Gabriel et al. (27).
Unadjusted measures of LD and association were assessed using the soft-
ware SNPGWA (http://www.phs.wfubmc.edu) (28). SNPGWA computes LD
statistics, D9 and r
2, for each pair of tandem SNPs. SNPGWA also performs
multiple tests of association including the overall two-degree of freedom test
(genotype), dominant model, recessive model, additive model (Cochran-
Armitage trend test), and the corresponding lack of ﬁt to the additive model.
Odds ratios, 95% conﬁdence intervals, and P values were computed for each
model of association. Population attributable risk (PAR) was calculated as
(X 2 1)/X. Assuming a log additive model, X =( 12 f )
2 +2 f(1 2 f )g + f
2g
2
where g is the estimated odds ratio (OR) and f is the risk allele frequency.
DG10S478 was converted to a biallelic marker for analysis.
Ancestry estimates were determined from 70 biallelic admixture informative
markers (AIMs) as previously described (16,29). Brieﬂy, AIMs were selected to
maximize European and African allele frequency differences and sample all
non-acrocentric arms of the autosomal genome. Reference population allele
frequencies were derived by genotyping 44 African (Yoruba from Ibadan,
Nigeria) and 39 European Americans. Individual ancestral proportions were
generated for each subject using FRAPPE (30), an expectation-maximization
algorithm, under a two-population model. The individual ancestral estimates
were used as covariates in the association analyses.
Conditional haplotype analysis. To test whether SNPs were independently
associated with type 2 diabetes, we performed an omnibus test for the hap-
lotype association using PLINK (31). We further adjusted the omnibus test by
controlling for one of the SNPs at a time. An insigniﬁcant conditional test
suggests that the conditioned SNP is sufﬁcient to explain the haplotype as-
sociation and there is a single, rather than multiple, association signals at the
haplotype.
RESULTS
Population characteristics. Characteristics of the African
American case-control populations are shown in Table 1.
Controls were signiﬁcantly younger than type 2 diabetic
cases (P < 0.0001), although they were signiﬁcantly older
than the mean age at type 2 diabetes diagnosis in the cases
(P < 0.0001). BMI was not signiﬁcantly different between
TABLE 1
Characteristics of African American study participants
Trait
Type 2 diabetic
ESRD cases Controls
n* Mean 6 SD n* Mean 6 SD
N 1,033 — 1,106 —
Women (%) 626 60.6 639 57.8
Age (years)
At exam 994 61.5 6 10.4 881 49.1 6 11.9
At type 2 diabetes
Ć diagnosis 965 41.4 6 12.4 ——
At ESRD diagnosis 960 57.9 6 10.9 ——
BMI (kg/m
2) 996 29.8 6 7.1 879 30.0 6 7.1
*Number with data available.
FIG. 1. Regional association plot for TCF7L2 610 kb (C10:114689999–
114926060). All SNPs genotyped on the Affy 6.0 array are plotted with
their 2log10 P values of association with type 2 diabetes versus the
genomic position (National Center for Biotechnology Information Build
36.1). The TCF7L2 gene position was taken from the University of
California, Santa Cruz genome browser (green), and the core region of
association (C10:114744078–114748339) analyzed by direct sequence
analysis is depicted in red. The most signiﬁcantly associated SNP from
the array is depicted as a blue diamond with its correlated proxies (red =
r
2 ‡ 0.80; orange = 0.50 ‡ r
2 > 0.80). SNP rs7903146 and microsatellite
DG10S478, depicted as gray circles, were typed independently in the
same set of samples. Estimated recombination rates from HapMap are
plotted in the background to depict the LD structure in the region.
(A high-quality color representation of this ﬁgure is available in the
online issue.)
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women were present in cases and controls (61% and 58%,
respectively). FRAPPE (30) analysis of AIM genotypes
estimated the mean proportion of African ancestry overall
was 0.79 6 0.12 and differed signiﬁcantly (P < 0.0001)
between type 2 diabetic cases and controls (0.80 6 0.12
and 0.78 6 0.12, respectively). Therefore, all results are
presented with adjustment for admixture.
Reﬁnement of the type 2 diabetes associated genomic
interval. A preliminary analysis assessed association with
type 2 diabetes for 59 SNPs across the entire 216-kb
TCF7L2 gene 610 kb from the Affymetrix 6.0 array-based
analysis of 965 type 2 diabetic ESRD cases and 1,029
controls (Fig. 1). With the use of the Tagger program of
Haploview (26), 43 of the 59 SNPs from the Affy array were
available in the HapMap YRI dataset and captured com-
mon variation at 121 SNPs (MAF .0.05; aggressive tag-
ging algorithm) with a mean r
2 = 0.73. Notably, the SNP
of greatest interest, rs7903146, is not typed on the Affy-
metrix 6.0 array. This SNP is located in a genomic interval
that is not tagged well (max r
2 = 0.45), resulting in only
nominal evidence of association in the Affymetrix 6.0
analysis. To circumvent limited coverage of the genetic
diversity in this speciﬁc region, imputation was used. Us-
ing data from HapMap phase II hybrid panel (1:1, YRI:
CEU), 108 SNPs were imputed across the TCF7L2 gene
6 10 kb (Supplementary Fig. 1). As a result, no variants
were identiﬁed with the same magnitude of signiﬁcance
as rs7903146. In a separate analysis, 497 SNPs were
imputed from the 1000 Genomes YRI Pilot 1 dataset
(Supplementary Fig. 2). As a result, two variants were
identiﬁed (rs33998771, chr10:114740378) proximal to
our region with signiﬁcant P values (3.58 3 10
25 and
3.29 3 10
25, respectively) similar to that of rs7903146. To
test whether these SNPs (rs33998771, chr10:114740378,
rs7903146) were independently associated with type 2 di-
abetes, we performed an omnibus test for the haplotype
association controlling for one SNP at a time. Four com-
mon haplotypes (ACT, ATT, TTT, and TTC) accounted for
99.9% of all haplotypes. These haplotype frequencies were
signiﬁcantly different between type 2 diabetic cases and
controls (0.042, 0.019, 0.268, and 0.672, respectively for
cases; 0.020, 0.016, 0.229, and 0.735, respectively for con-
trols, omnibus test P = 5.4 3 10
26), with the haplotypes
TTC and ACT strongly associated with protection and risk
for type 2 diabetes, respectively (P < 0.0001). Omnibus
analysis revealed that the haplotype association was sig-
niﬁcantly reduced after adjusting for rs7903146 (P = 0.023),
whereas strong association remained by conditioning
rs33998771 or chr10:114740378 (P = 0.0006 and 0.002, re-
spectively), suggesting that rs7903146 alone explained
most of the haplotype association.
These results lead us to focus on a single region span-
ning ;16.5 kb. Fourteen additional SNPs were genotyped
in an expanded set of type 2 diabetic cases and controls
within this interval and analyzed for association as sum-
marized in Table 2. The core region of association was
between SNPs rs4132115 and rs7903146 (admixture-
adjusted additive P values ranging from 0.012 to 2.38 3
10
26). This region encompasses a 4.3-kb LD block in the
YRI population (HapMap Phase II YRI data), which is
bounded by the two SNPs rs7901695 and the previously
associated rs7903146 (16).
In addition, the previously associated (21) microsatellite
marker DG10S478, which lies 38 kb distal to and outside of
this LD block, was typed, and the results of the analysis are
TABLE 3
DG10S478 allelic association with type 2 diabetes ESRD in
African Americans
Allele
Frequency
OR P value
Cases
(n = 1,910)
Controls
(n = 1,972)
28 0.00052 0.0010 0.52 0.59
24 0.0063 0.012 0.47 0.043
0 0.72 0.73 0.91 0.21
4 0.11 0.11 1.14 0.20
8 0.081 0.064 1.33 0.022
12 0.059 0.049 1.27 0.10
16 0.016 0.032 0.39 5.02 3 10
25
20 0.0052 0.0056 0.94 0.89
TABLE 2
Single SNP genotypic association results for SNPs in the TCF7L2 gene showing association with type 2 diabetes ESRD
Marker
Chromosome
position (bp) Alleles
MAF
OR (95% CI)
Additive
P value
Cases
(n = 982)
Controls
(n = 1,039)
rs7079711* 114735778 G/A 0.44 0.43 1.00 (0.88–1.13) 0.99
rs4074720 114738737 T/C 0.23 0.25 0.95 (0.82–1.11) 0.53
rs4074718 114738857 A/G 0.23 0.25 0.93 (0.80–1.08) 0.35
rs11196182* 114740397 C/T 0.26 0.28 0.85 (0.74–0.98) 0.025
rs17747324† 114742743 T/C 0.08 0.07 1.26 (0.99–1.60) 0.058
rs4132115 114745736 G/T 0.19 0.15 1.23 (1.04–1.46) 0.014
rs4506565 114746281 A/T 0.51 0.47 1.15 (1.01–1.30) 0.030
rs7068741 114746498 C/T 0.19 0.15 1.24 (1.05–1.46) 0.012
rs7069007 114746525 G/C 0.14 0.11 1.23 (1.02–1.48) 0.033
rs7903146 114748589 C/T 0.35 0.29 1.35 (1.18–1.54) 1.76 3 10
25
rs11196187 114749685 G/A 0.06 0.05 1.29 (0.97–1.71) 0.082
rs7092484 114751173 G/A 0.28 0.26 1.07 (0.93–1.23) 0.35
rs12098651* 114751959 G/A 0.24 0.22 1.09 (0.94–1.26) 0.25
rs6585198 114752477 A/G 0.18 0.21 0.85 (0.73–1.00) 0.051
*Inconsistent with HWE in cases. †Inconsistent with HWE in controls.
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consistent with prior genotyping in samples from African
populations (15). Evidence of association was observed
with the protective alleles 24 and 16 (P = 0.043 and 5.02 3
10
25, respectively) and the risk allele 8 (P = 0.022).
Direct sequence analysis and association analysis of
the associated genomic interval. The core region of
association (C10:114744078–114748339) 6 2 kb was an-
alyzed by direct sequence analysis in 96 samples (48 type 2
diabetic cases and 48 controls). A total of 46 SNPs were
identiﬁed, of which 72% (33/46) were novel and 17% (8/46)
had a MAF .5%. When genotyped in the expanded cohort,
ﬁve of the novel SNPs were found to be monomorphic and
10 could not be typed on the Sequenom platform because
of the repetitive nature of the region. These 10 were geno-
typed via direct sequence analysis on a subset of 96 type 2
diabetic cases and 96 controls. Four SNPs were common,
and these sequencing data were paired with existing data
to be used as the known set of haplotypes for imputation
in the remaining cohort. In addition, rs61875120 was
common but yielded poor quality imputation (rsq = 0.31)
and was therefore genotyped by direct sequence analysis.
TABLE 4
Single SNP genotypic association results for SNPs identiﬁed by direct sequence analysis in the TCF7L2 gene showing association with
type 2 diabetes ESRD
Variant ID
Position Alleles
MAF
OR (95% CI)
Additive
P value rs No. Sequence ID
Cases
(n = 1,033)
Controls
(n = 1,106)
IVS3 +41490 114742846 C/2 0.00 0.00 ——
IVS3 +41661 114743017 C/2 0.00 0.00 ——
rs61875120 IVS3 +41847 114743203 T/C 0.08 0.07 1.29 (1.03–1.62) 0.029
IVS3 +41893† 114743249 T/C 0.07 0.07 1.14 (0.90–1.44) 0.28
IVS3 +42112 114743468 C/2 0.00 0.00 ——
IVS3 +42245* 114743601 ——
IVS3 +42428* 114743784 ——
rs34347733† IVS3 +42434 114743790 C/T 0.11 0.10 1.14 (0.94–1.39) 0.19
rs34872471 IVS3 +42705 114744061 T/C 0.40 0.34 1.30 (1.14–1.48) 8.34 3 10
25
rs7901695 IVS3 +42722 114744078 T/C 0.50 0.47 1.16 (1.03–1.32) 0.017
IVS3 +43235† 114744591 G/A 0.18 0.15 1.26 (1.07–1.49) 0.0053
rs35198068† IVS3 +43418 114744774 T/C 0.40 0.34 1.31 (1.15–1.48) 2.91 3 10
25
IVS3 +43487* 114744843 ——
IVS3 +43552 114744908 C/T 0.02 0.01 1.80 (1.04–3.11) 0.036
IVS3 +43592 114744948 C/T 0.01 0.01 1.64 (0.86–3.11) 0.13
rs4132115 IVS3 +44130 114745486 G/T 0.18 0.15 1.29 (1.09–1.53) 0.0034
IVS4 244095 114745679 C/G 0.05 0.05 0.94 (0.71–1.25) 0.68
IVS4 244055 114745719 C/G 0.04 0.04 0.90 (0.66–1.23) 0.51
IVS4 243836 114745938 A/G 0.01 0.01 0.98 (0.48–1.99) 0.95
IVS4 243759 114746015 T/2 0.00 0.00 ——
rs4506565 IVS4 243743 114746031 A/T 0.50 0.45 1.20 (1.06–1.36) 0.0051
IVS4 243705 114746069 A/G 0.001 0.004 0.40 (0.11–1.49) 0.17
rs7068741 IVS4 243526 114746248 C/T 0.18 0.15 1.25 (1.05–1.48) 0.010
IVS4 243522 114746252 ——
rs7069007 IVS4 243499 114746275 G/C 0.13 0.11 1.29 (1.07–1.57) 0.0085
IVS4 243352 114746422 T/C 0.01 0.01 1.65 (0.87–3.13) 0.12
IVS4 243090 114746684 A/G 0.05 0.04 1.15 (0.84–1.56) 0.38
IVS4 243040§ 114746734 G/A 0.001 0.004 0.39 (0.11–1.38) 0.14
IVS4 243007 114746767 ——
IVS4 242978 114746796 C/T 0.18 0.15 1.25 (1.04–1.50) 0.019
IVS4 242945 114746829 G/T 0.01 0.01 1.55 (0.82–2.95) 0.18
IVS4 242705 114747069 A/T 0.002 0.003 0.74 (0.21–2.64) 0.64
IVS4 242695 114747079 T/2 0.00 0.00 ——
rs35676242 IVS4 242470 114747304 C/A 0.02 0.02 1.44 (0.90–2.30) 0.13
IVS4 242326 114747448 G/A 0.07 0.07 0.95 (0.74–1.22) 0.70
IVS4 242248 114747526 G/C 0.03 0.03 0.92 (0.62–1.36) 0.66
IVS4 242148 114747626 A/G 0.02 0.01 1.75 (1.03–2.98) 0.039
IVS4 242079 114747695 A/T 0.01 0.01 1.41 (0.75–2.64) 0.29
IVS4 241828 114747946 C/G 0.13 0.13 0.93 (0.78–1.13) 0.48
IVS4 241672 114748102 C/T 0.01 0.01 1.11 (0.57–2.15) 0.75
IVS4 241633§ 114748141 G/C 0.01 0.01 1.64 (0.72–3.77) 0.24
rs7903146‡§ IVS4 241435 114748339 C/T 0.34 0.28 1.37 (1.19–1.57) 6.32 3 10
26
IVS4 241323§ 114748451 G/A 0.02 0.03 0.65 (0.43–0.99) 0.043
IVS4 241264 114748510 C/T 0.07 0.07 0.89 (0.69–1.14) 0.36
rs4267006§ IVS4 241005 114748769 G/T 0.06 0.05 1.22 (0.93–1.60) 0.14
rs35801464 IVS4 239500 114750274 C/T 0.06 0.05 1.32 (1.00–1.75) 0.050
*Low MAF in 96 samples resulting in poor imputation. †Imputed genotypes. ‡Inconsistent with HWE in cases. §Inconsistent with HWE in
controls.
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TCF7L2 IN AFRICAN AMERICANS
666 DIABETES, VOL. 60, FEBRUARY 2011 diabetes.diabetesjournals.orgThe remaining ﬁve SNPs had low MAF (MAF <0.05) and
were not genotyped. Table 4 summarizes sequence var-
iants and association analysis results. Of the 36 SNPs typed
or imputed, 15 SNPs were found to be nominally asso-
ciated with type 2 diabetes (admixture-adjusted additive
P values ranging from 0.050 to 6.32 3 10
26). The most
striking associations were observed at rs34872471,
rs35198068 (imputed), and rs7903146, which were corre-
lated (r
2 . 0.74; Fig. 2) and associated with disease sus-
ceptibility (OR = 1.30–1.37) under an additive model. Three
common haplotypes (CCT, CCC, and TTC) accounted for
99.6% of all haplotypes. These haplotype frequencies were
signiﬁcantly different between type 2 diabetic cases and
controls (0.342, 0.056, and 0.602, respectively for cases;
0.278, 0.058, and 0.664, respectively for controls, omnibus
test P = 3.7 3 10
25). Omnibus analysis revealed that the
haplotype association was lost after adjusting for rs7903146
(P = 0.85), whereas modest association remained by con-
ditioning rs34872471 or rs35198068 (P = 0.05), suggesting
that rs7903146 alone is sufﬁcient to explain the overall
haplotype association.
DISCUSSION
This study illustrates the power of genetic analyses in
African-derived populations to facilitate identiﬁcation of
trait-deﬁning variants. TCF7L2 has been identiﬁed as one
of the strongest type 2 diabetes susceptibility genes to date
with associations across multiple ethnically diverse pop-
ulations (12,15,16,21,32). Our study is consistent with the
initial association of SNP rs7903146 in an African Ameri-
can type 2 diabetic case-control population. By taking
advantage of reduced LD in the African American pop-
ulation, we have been able to narrow the critical interval
for association. This 4.3-kb region, ﬂanked by SNPs
rs4132115 and rs7903146, was the focus of resequencing in
an effort to infer which sequence variant(s) are causally
associated with type 2 diabetes.
Of the 46 SNPs identiﬁed by resequencing, 15 SNPs were
nominally associated with type 2 diabetes with the most
signiﬁcant associations observed at rs34872471, rs35198068
(imputed), and rs7903146, which were highly correlated
(r
2 . 0.74; Fig. 1) and associated with disease susceptibility
(OR = 1.30–1.37). Conditional omnibus haplotype analysis
suggested that rs7903146 was sufﬁcient to explain the
haplotype association. This analysis suggests that associa-
tion at rs34872471 and rs35198068 was the result of corre-
lation with the true signal from rs7903146.
Although this study has eliminated the possibility of
additional common variants (MAF .0.01) contributing
to type 2 diabetes susceptibility within the ﬁne-mapped
interval (C10:114744078–114748339 6 2 kb) of the
TCF7L2 locus, four variants (IVS3 +42245, IVS3 +42428,
IVS3 +43487, and IVS4 243007) were found to have MAF
<0.01. These variants, which were located in highly re-
petitive regions, were not evaluated. To date these var-
iants have not been identiﬁed by other ongoing studies,
i.e., the 1000 Genomes project, suggesting they are private
mutations. Additionally, given the low MAF, these variants
are not likely to explain the association observed at the
TCF7L2 locus, but we cannot rule out the possibility that
these and other unidentiﬁed rare variants contribute to
disease susceptibility. If this were so, effect sizes of such
rare variants would have to be in a range unprecedented for
noncoding variants.
As a result of ﬁne-mapping the TCF7L2 locus to de-
termine the region most likely to harbor susceptibility
variants, the microsatellite marker DG10S478 was ex-
cluded as the causal variant. DG10S478 is located 41 kb
proximal to the critical interval deﬁned in the African
American population and is in weak LD with rs7903146
(D9 = 0.35, r
2 = 0.07). Only a single common allele of
DG10S478 is nominally associated with type 2 diabetes,
with the strongest association, which is protective, seen
with low MAF variants. These data suggest that the con-
tribution to disease by DG10S478 is nominal.
This study represents the ﬁrst comprehensive evaluation
of variation within the TCF7L2 gene in a large African
American population. Taking advantage of the LD struc-
ture in our African-derived sample of African Americans,
we were able to reduce the genomic interval of association
to ;4.3 kb and exclude the possible contribution of the
previously identiﬁed microsatellite marker to type 2 dia-
betes susceptibility. Our analysis identiﬁed three SNPs,
rs34872471, rs35198068 (imputed), and rs7903146, which
were highly associated with type 2 diabetes; all had P values
that were two orders of magnitude stronger than other
SNPs. Conditional omnibus haplotype analysis suggested
that rs7903146 was sufﬁcient to explain the haplotype as-
sociation. SNP rs7903146 remains the most signiﬁcantly
associated variant within the TCF7L2 gene with a calcu-
lated PAR of 17.4%.
This investigation has used genetic approaches to focus
on rs7903146. Alternative explanations can be proposed.
For example, rs7903146 could be in LD with an unknown
common variant. We cannot exclude this possibility with
total conﬁdence, but the assessment of markers in TCF7L2
by direct genotyping, imputation, and then through the use
of the 1000 Genomes data using conditional analysis sug-
gests the likelihood that such a common variant exists is
low. Evaluation of long range LD on chromosome 10 shows
little evidence for a remote variant (data not shown). An
alternative is the possibility that a rare variant of large effect
in LD with rs7903146 is the actual functional variant. This
also seems unlikely. Although theoretically possible (33),
we have recently shown empirically that it is easy to dif-
ferentiate between a rare functional variant with large effect
and a common variant in LD (34).
Thus, ﬁne-mapping at the TCF7L2 locus using an Af-
rican ancestry population has statistically implicated
rs7903146 as the causal variant. It is noteworthy that
Gaulton et al. (20) have implicated rs7903146 as a func-
tional variant by mapping sequence variants to open
chromatin sites. They found that rs7903146 is located in
islet-selective open chromatin, and human islet samples
heterozygous for rs7903146 showed allelic imbalance in
islet enhancer activity. Thus genetic and functional stud-
ies make a consistent case for a functional role for
rs7903146.
scores (LOD <2) are shown in white. The number within each box indicates the r
2 value. B: Haploview-generated LD map of the 17 common SNPs
(MAF >0.05) identiﬁed by direct sequence analysis (C10:114742846–114750274) in African American controls (n = 1,106). Regions of high LD
(D9 = 1 and LOD >2) are shown in dark red. Markers with lower LD (0.45 < D9 < 1 and LOD >2) are shown in light red, with the color intensity
decreasing with decreasing D9 value. Regions of low LD and low LOD scores (LOD <2) are shown in white. The number within each box indicates
the r
2 value. (A high-quality color representation of this ﬁgure is available in the online issue.)
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